Revolution Medicines, a commercial-stage oncology company focused on RAS-addicted cancers, will announce its financial results for the third quarter of 2026 on November 4, 2026, after market close. The company will host a webcast at 4:30 p.m. ET to discuss the results and provide updates on corporate progress. This event is significant for investors tracking the company's development of innovative cancer treatments, especially its RAS(ON) tri-complex inhibitor platform. A replay of the webcast will be available on the company's website for at least 14 days.
Revolution Medicines (RVMD) shares are trading at USD 194.57 on Pluang as of Oct 22, 2026 03:11 WIB, down 1.01% for the day. This price is closer to the 52-week high of USD 221.15 than the low of USD 52.98, indicating strong investor interest despite the recent slight decline. The company's market cap stands at $42.14 billion, reflecting its significant position in the health sector. The typical hold time on Pluang is 6 days, showing moderate trading activity around this stock.
